Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity
Obesity · 2025-07 · 33 (7) · 1297-1308
DOI: 10.1002/oby.24310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, online erschienen am 13.06.2025. Verfasst von Meredith M Hoog und 10 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Obesity, Overweight. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Objective
Our objective was to model the potential cost‐effectiveness of tirzepatide as an alternative to lifestyle modification (LSM) for the management of obesity and overweight.
Methods
An individual‐level discrete event simulation was implemented in Microsoft Excel linking short‐term outcomes from the SURMOUNT‐1 trial to key obesity‐related complications to estimate costs and health benefits of tirzepatide (5‐mg, 10‐mg, or 15‐mg doses) and LSM over a lifetime time horizon. Treatment‐related changes in cardiometabolic factors were modeled using data from SURMOUNT‐1; the relationship between patient status and risk of obesity complications was obtained from published literature. Modeled complications included cardiovascular events, onset of type 2 diabetes, cancer, osteoarthritis, and sleep apnea. The model simulated 1000 adult patients with overweight or obesity over their lifetimes, applying a 3% annual discount rate to cost and health outcomes. Only direct medical costs were considered.
Results
Tirzepatide 5, 10, and 15 mg provided 0.54, 0.55, and 0.61 additional quality‐adjusted life years (QALYs) and additional costs of $79,288, $70,453, and $75,839 versus LSM, yielding incremental cost‐effectiveness ratios of $146,331, $127,644, and $125,053 per QALY gained, respectively.
Conclusions
The model predicted that all doses of tirzepatide represent cost‐effective alternatives to LSM for management of overweight and obesity at a willingness‐to‐pay threshold of $150,000 per QALY.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Evidera Inc., Wilmington, North Carolina, USA.
- Evidera, Budapest, Hungary.
ORCID-Profile: Meredith M Hoog, Lisa M Neff
Förderung
- Eli Lilly and Company
Zitieren
APA
Hoog, M. M., Kan, H., Deger, K. A., Sorensen, S., Neff, L. M., Bae, J. P., Hankosky, E. R., Murphy, M., Mojdami, D., Houisse, I., & Harris, M. S. (2025). Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity. Obesity, 33(7), 1297-1308. https://doi.org/10.1002/oby.24310
Vancouver
Hoog MM, Kan H, Deger KA, Sorensen S, Neff LM, Bae JP, et al. Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity. Obesity. 2025;33(7):1297-1308. doi:10.1002/oby.24310
BibTeX
@article{Hoog2025,
author = {Hoog, Meredith M and Kan, Hong and Deger, Kristen A and Sorensen, Sonja and Neff, Lisa M and Bae, Jay Patrick and Hankosky, Emily Ruth and Murphy, Madhumita and Mojdami, Donna and Houisse, Ivan and Harris, Mack S},
title = {Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity},
journal = {Obesity},
year = {2025},
volume = {33},
number = {7},
pages = {1297--1308},
doi = {10.1002/oby.24310}
}
EUVIMED